Dsuvia is a Small Molecule owned by AcelRx Pharmaceuticals, and is involved in 25 clinical trials, of which 20 were completed, 2 are ongoing, and 3 are planned.

Sufentanil is a Mu opioid receptor agonist. It interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited.

The revenue for Dsuvia is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dsuvia NPV Report.

Dsuvia is currently owned by AcelRx Pharmaceuticals.

Dsuvia Overview

Sufentanil citrate (Dzuveo, ARX-F01, Dsuvia) is an anilide derivative, acts as an opioid anesthetic agent with analgesic properties. It is formulated as tablets for the sublingual route of administration. Dzuveo is indicated for the management of acute moderate to severe pain and in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Sufentanil citrate (ARX-04) is under development for the treatment of moderate-to-severe acute pain in a medically supervised setting, including medically supervised patients in an emergency, outpatient or ambulatory surgery, non-surgical patients experiencing pain and post-operative pain in patients, after short-stay surgery. The drug candidate is developed based on NanoTab technology.

AcelRx Pharmaceuticals Overview

AcelRx Pharmaceuticals (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo in Europe), is a single sufentanil sublingual tablet for treating of moderate-to-severe acute pain. Its pipeline also includes Zalviso (for US market), a drug and device combination product for the management of moderate to severe acute pain in adults. AcelRx developed a proprietary, non-invasive, sublingual formulation technology to deliver its highly lipophilic drugs. The company commercializes its EC-approved Zalviso under a license agreement with Grunenthal in Europe and Australia. AcelRx is headquartered in Hayward, California, the US.

The company reported revenues of (US Dollars) US$2.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 48% over FY2020. The operating loss of the company was US$36 million in FY2021, compared to an operating loss of US$41 million in FY2020. The net loss of the company was US$35.1 million in FY2021, compared to a net loss of US$40.4 million in FY2020. The company reported revenues of US$0.5 million for the third quarter ended September 2022, a decrease of 49.9% over the previous quarter.

Quick View – Dsuvia

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Dsuvia
Administration Pathway
  • Sublingual
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.